<i>MGMT</i> promoter methylation and <i>IDH1</i> mutation as prognostic markers for a favorable clinical outcome in patients with glioblastoma multiforme.
Agnieszka Woźniak(VIB-KU Leuven Center for Cancer Biology), Paul M. Clément(Universitair Ziekenhuis Leuven), J. Menten, Maria Dêbiec‐Rychter(Center for Human Genetics), F Van Calenbergh, Hilko Ardon, Steven De Vleeschouwer(KU Leuven), Raf Sciot(KU Leuven), Stefaan Van Gool, Elke Van Mieghem(VIB-KU Leuven Center for Cancer Biology)
Cited by 1
Related Papers
Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994
NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST)—Update of the NCCN Clinical Practice Guidelines
|Journal of the National Comprehensive Cancer Network|2007|636
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
|Journal of Clinical Oncology|2009|573